CURATIS N AG Unternehmensprofil

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilsons disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, gastroenterologic, immunomodulator, thyreostatic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntingtons disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema in pediatric patients; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and KIN001 that is in Phase I clinical trial for the treatment of rare inflammatory and fibrotic diseases. The company is based in Liestal, Switzerland.

Nennwert/Aktie	-
Land	Schweiz
Währung	CHF
Branche	Medikamente
Aktientyp	-
Sektor	Gesundheit
Gattung	-